Jill Ohar, MD
Professor, Pulmonary, Critical Care, Allergy, and Immunologic Medicine Comprehensive Cancer Center Center for Worker Health Director, Respiratory Care Wake Forest Baptist Health Winston-Salem, NC
AMA PRA Category 1 Credit™ Medium
Mobile + Online on QuantiaMD
This activity will help clinicians achieve greater competency in managing exacerbations of COPD and optimizing the use of nonpharmacologic and pharmacologic interventions in tailored COPD treatment plans.
. Target Audience
This educational activity is designed to meet the needs of community pulmonologists and primary care clinicians involved in the care of patients with COPD.
Upon completion of this educational activity, the participant should be able to:
Assess the severity of COPD exacerbations.
Compare the efficacy and safety of pharmacologic options available for the treatment of COPD exacerbations.
Differentiate COPD exacerbations from CHF exacerbations.
Jill Ohar, MD, discloses the following relationships with commercial interests:
Advisory Board—Sunovion, Novartis, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc.
Rick Ricer, MD, Physician Reviewer, University of Cincinnati, has no conflicts of interest to disclose.
Susan P. Tyler, MEd, CMP, CHCP, FACEHP, University of Cincinnati, has no conflicts of interest to disclose.
Lillian McVey, Medical Writer, has no conflicts of interest to disclose.
Kathleen Hines, MCM Editorial Director, has no conflicts of interest to disclose.
The University of Cincinnati requires all faculty to disclose any planned discussion of an investigational and/or off-label use of a pharmaceutical product or device within their presentation. Participants should note that the use of products outside FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for approved indications.
In this educational activity, the faculty reports her presentation will not contain reference to investigational and/or off-label uses.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and MCM Education. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.
The University of Cincinnati designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Release date: January 29, 2016
Last review date: January 29, 2016
Expiration date: January 29, 2017 Commercial Support Statements
This activity is supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Novartis.
* Click "Start Program" and log into program on QuantiaMD.com
* Take the pre-test
* Review the activity
* Take the post-test and score 80%
* You are allowed a total of 3 attempts
* Complete the evaluation
* View, print, or save a CME certificate verifying your
credit/participation in this activity
Computer Requirements: Minimum System Requirements: • Pentium III, 600 MHz or Equivalent Processor • 512 MB of RAM • Windows XP, Vista, or 7 • Mac OS X • 800x600 Monitor Resolution • 16-bit Color • 16 bit Sound Card with Speakers
There is no charge for CME credit.
© 2016 MCM Education. All rights reserved. None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, the University of Cincinnati, Boehringer Ingelheim Pharmaceuticals, Inc., or Novartis. Any medications, diagnostic procedures, or treatments discussed by the faculty should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.